Gastrointestinal therapeutics in major developed market 2019 : Radiant Insights, Inc

Gastrointestinal Therapeutics in Major Developed Market 2019 – Industry Analysis, Market Size, Competitive Trends: Radiant Insights, Inc Summary GBI Research, the leading business intelligence provider, has released its latest research, 'Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries', which provides insights into three gastrointestinal therapeutic indications in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an in-depth analysis of three gastrointestinal therapeutics markets, namely Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn's Disease (CD). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three gastrointestinal indications.

View Full Report with TOC @ http://www.radiantinsights.com/research/gastrointestinaltherapeutics-in-major-developed-markets-to-2019-new-drug-approvals-and-promising-pipeline-tocounter-declines-from-patent-expiries The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by GBI Research's team of industry experts.

In 2012, the value of the gastrointestinal therapeutics market in major developed countries amounted to an estimated $6.8 billion. This total is forecast to decline at a Compound Annual Growth Rate (CAGR) of 0.3% between 2012 and 2019. The value of the IBS market amounted to an estimated $727m, and is forecast to increase at a CAGR of 14.4% between 2012 and 2019. The value of the UC market amounted to an estimated $2.2 billion in 2012, and is expected to increase at a CAGR of 6% during the forecast period. The value of the CD market amounted to an estimated $3.8 billion, which is expected to decline at a CAGR of 7.5% between 2012 and 2019.

Scope - The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals for the IBS, UC and CD indications in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada.

- Disease overview and treatment usage patterns - Market size and forecast for IBS, UC and CD in major developed markets from 2012 to 2019 - Major marketed products for the indication types covered - In-depth pipeline analysis for IBS, UC and CD

- Key drivers and restraints that have had and are expected to have a major impact upon the market - Key licensing and co-development agreements in the gastrointestinal therapeutics market Reasons to buy - Align your product portfolio to the markets with high growth potential - Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments that are poised for strong growth - Devise a more effectively tailored country-specific strategy through the understanding of key drivers and barriers in the gastrointestinal therapeutics market - Develop key strategic initiatives based upon an understanding of key focus areas and leading companies - Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships View Full Report with TOC @ http://www.radiantinsights.com/research/gastrointestinaltherapeutics-in-major-developed-markets-to-2019-new-drug-approvals-and-promising-pipeline-tocounter-declines-from-patent-expiries Table of Contents Table of Contents 6 1.1 List of Tables 9 1.2 List of Figures 10 2 Gastrointestinal Therapeutics in Major Developed Markets - Introduction 11 2.1 Irritable Bowel Syndrome 11 2.1.1 Classification 11 2.1.2 Symptoms 11 2.1.3 Etiology 11 2.1.4 Pathophysiology 12 2.1.5 Diagnosis 12 2.1.6 Epidemiology 13 2.1.7 Prognosis 14 2.1.8 Treatment Options 14

2.2 Ulcerative Colitis 15 2.2.1 Classification 15 2.2.2 Symptoms 16 2.2.3 Etiology 16 2.2.4 Pathophysiology 17 2.2.5 Diagnosis 17 2.2.6 Epidemiology 18 View Full Report with TOC @ http://www.radiantinsights.com/research/gastrointestinaltherapeutics-in-major-developed-markets-to-2019-new-drug-approvals-and-promising-pipeline-tocounter-declines-from-patent-expiries 2.2.7 Prognosis 18 2.2.8 Treatment Options 19 2.3 Crohn's Disease 20 2.3.1 Classification 20 2.3.2 Symptoms 21 2.3.3 Etiology 21 2.3.4 Pathophysiology 22 2.3.5 Diagnosis 22 2.3.6 Epidemiology 23 2.3.7 Prognosis 23 2.3.8 Treatment Options 24 3 Gastrointestinal Therapeutics in Major Developed Markets - Marketed Products (Global) 25 3.1 Irritable Bowel Syndrome 25 3.2 Ulcerative Colitis 25 3.3 Crohn's Disease 25 3.4 Key Marketed Products 26 3.4.1 Amitiza 26

3.4.2 Humira 27 3.4.3 Remicade 28 3.4.4 Simponi 29 3.4.5 Cimzia 30 3.4.6 Tysabri 31 View Full Report with TOC @ http://www.radiantinsights.com/research/gastrointestinaltherapeutics-in-major-developed-markets-to-2019-new-drug-approvals-and-promising-pipeline-tocounter-declines-from-patent-expiries 4 Gastrointestinal Therapeutics in Major Developed Markets - Pipeline Analysis 33 4.1 Irritable Bowel Syndrome 33 4.1.1 Overall Pipeline 33 4.1.2 Pipeline Analysis by Molecule Type 35 4.1.3 Pipeline Analysis by Mechanism of Action 36 4.2 Ulcerative Colitis Pipeline 38 4.2.1 Overall Pipeline 38 4.2.2 Pipeline Analysis by Molecule Type 40 4.2.3 Pipeline Analysis by Mechanism of Action 41 4.3 Crohn's Disease Pipeline 43 4.3.1 Overall Pipeline 43 4.3.2 Pipeline Analysis by Molecule Type 45 4.3.3 Pipeline Analysis by Mechanism of Action 46 4.4 Promising Drug Candidates in the Pipeline 48 4.4.1 GSK-1605786 48 4.4.2 MLN0002 48 4.4.3 EMD-61753 48 5 Gastrointestinal Therapeutics in Major Developed Markets - Market Forecast to 2019 49 5.1 Major Developed Markets 49

5.1.1 Treatment Usage Patterns 49 5.1.2 Annual Cost of Therapy 49 5.1.3 Market Size 49 5.2 US 51 5.2.1 Treatment Usage Patterns 51 5.2.2 Annual Cost of Therapy 51 5.2.3 Market Size 51 5.3 Europe 53 View Full Report with TOC @ http://www.radiantinsights.com/research/gastrointestinaltherapeutics-in-major-developed-markets-to-2019-new-drug-approvals-and-promising-pipeline-tocounter-declines-from-patent-expiries 5.3.1 Treatment Usage Patterns 53 5.3.2 Annual Cost of Therapy 53 5.3.3 Market Size 53 5.4 Canada 55 5.4.1 Treatment Usage Patterns 55 5.4.2 Annual Cost of Therapy 55 5.4.3 Market Size 55 5.5 Japan 57 5.5.1 Treatment Usage Patterns 57 5.5.2 Annual Cost of Therapy 57 5.5.3 Market Size 57 5.6 Drivers and Barriers 59 5.6.1 Drivers 59 5.6.2 Barriers 59 6 Gastrointestinal Therapeutics in Major Developed Markets - Deals and Strategic Consolidations (Global) 61

6.1 Deals Analysis 61 6.2 Major Co-Development Deals 63 6.2.1 AstraZeneca Enters into Co-Development Agreement with Ironwood Pharma for Linaclotide 64 6.2.2 Amgen Enters into Co-development Agreement with AstraZeneca for Five Monoclonal Antibodies 64 6.2.3 Galapagos and AbbVie Extend GLPG0634 Development Agreement to Include Crohn's Disease 64 6.3 Major Licensing Deals 65 6.3.1 AstraZeneca Enters into Licensing Agreement with Ardelyx for NHE3 Inhibitor Program 66 6.3.2 Sanofi-Aventis Enters into Licensing Agreement with Kyowa Hakko Kirin 66 6.3.3 GlaxoSmithKline Enters into Licensing Agreement with ChemoCentryx 66 View Full Report with TOC @ http://www.radiantinsights.com/research/gastrointestinaltherapeutics-in-major-developed-markets-to-2019-new-drug-approvals-and-promising-pipeline-tocounter-declines-from-patent-expiries 7 Gastrointestinal Therapeutics in Major Developed Markets - Appendix 67 7.1 All Pipeline Drugs by Phase 67 7.1.1 Discovery 67 7.1.2 Preclinical 67 7.1.3 IND/CTA-filed 68 7.1.4 Phase I 69 7.1.5 Phase II 70 7.1.6 Phase III 72 7.1.7 Pre-Registration 72 7.1.8 Undisclosed 73 7.2 Market Forecasts to 2019 73 7.2.1 Major Developed Markets 73 7.2.2 US 74 7.2.3 Canada 75

7.2.4 UK 76 7.2.5 France 77 7.2.6 Germany 78 7.2.7 Italy 79 7.2.8 Spain 80 7.2.9 Japan 81 7.3 Market Definitions 82 View Full Report with TOC @ http://www.radiantinsights.com/research/gastrointestinaltherapeutics-in-major-developed-markets-to-2019-new-drug-approvals-and-promising-pipeline-tocounter-declines-from-patent-expiries 7.4 Abbreviations 82 7.5 Sources 84 7.6 Research Methodology 86 7.6.1 Coverage 86 7.6.2 Secondary Research 86 7.6.3 Primary Research 87 7.6.4 Therapeutic Landscape 87 7.6.5 Geographical Landscape 90 7.6.6 Pipeline Analysis 90 7.7 Expert Panel Validation 90 7.8 Contact Us 90 7.9 Disclaimer 90 List of Tables Table 1: Gastrointestinal Therapeutics Market, Irritable Bowel Syndrome, Classification, 2009 11 Table 2: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Recommendations for Irritable Bowel Syndrome, 2009 15

Table 3: Gastrointestinal Therapeutics Market, Major Developed Markets, Classification of Ulcerative Colitis, 2004 15 Table 4: Gastrointestinal Therapeutics Market, Major Developed Markets, Diagnosis of Ulcerative Colitis, 2007 17 Table 5: Gastrointestinal Therapeutics Market, Major Developed Markets, Difference Between Ulcerative Colitis and Crohn's Disease, 2007 18 Table 6: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Options of Ulcerative Colitis, 2011 20 Table 7: Gastrointestinal Therapeutics Market, Major Developed Markets, Classification of Crohn's Disease, 2013 20 Table 8: Gastrointestinal Therapeutics Market, Major Developed Markets, Symptoms of Crohn's Disease, 2012 21 Table 9: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Options for Crohn's Disease , 2009 24 View Full Report with TOC @ http://www.radiantinsights.com/research/gastrointestinaltherapeutics-in-major-developed-markets-to-2019-new-drug-approvals-and-promising-pipeline-tocounter-declines-from-patent-expiries Table 10: Gastrointestinal Therapeutics Market, Global, Pipeline (Discovery), 2013 67 Table 11: Gastrointestinal Therapeutics Market, Global, Pipeline (Preclinical), 2013 67 Table 12: Gastrointestinal Therapeutics Market, Global, Pipeline (IND/CTA-filed), 2013 68 Table 13: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase I), 2013 69 Table 14: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase II), 2013 70 Table 15: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase III), 2013 72 Table 16: Gastrointestinal Therapeutics Market, Global, Pipeline (Pre-Registration), 2013 72 Table 17: Gastrointestinal Therapeutics Market, Global, Pipeline (Undisclosed), 2012 73 Table 18: Gastrointestinal Therapeutics Major Developed Markets, Irritable Bowel Syndrome, Market Forecast, 2012-2019 73 Table 19: Gastrointestinal Therapeutics Market, Major Developed Markets, Ulcerative Colitis, Market Forecast, 2012-2019 74 Table 20: Gastrointestinal Therapeutics Market, Major Developed Markets, Crohn's Disease, Market Forecast, 2012-2019 74

Table 21: Gastrointestinal Therapeutics Market, US, Irritable Bowel Syndrome, Market Forecast, 20122019 74 Table 22: Gastrointestinal Therapeutics Market, US, Ulcerative Colitis, Market Forecast, 2012-2019 75 Table 23: Gastrointestinal Therapeutics Market, US, Crohn's Disease, Market Forecast, 2012-2019 75 Table 24: Gastrointestinal Therapeutics Market, Canada, Irritable Bowel Syndrome, Market Forecast, 2012-2019 75 Table 25: Gastrointestinal Therapeutics Market, Canada, Ulcerative Colitis, Market Forecast, 2012-2019 76 Table 26: Gastrointestinal Therapeutics Market, Canada, Crohn's Disease, Market Forecast, 2012-2019 76 Table 27: Gastrointestinal Therapeutics Market, UK, Irritable Bowel Syndrome, Market Forecast, 20122019 76 View Full Report with TOC @ http://www.radiantinsights.com/research/gastrointestinaltherapeutics-in-major-developed-markets-to-2019-new-drug-approvals-and-promising-pipeline-tocounter-declines-from-patent-expiries Table 28: Gastrointestinal Therapeutics Market, UK, Ulcerative Colitis, Market Forecast, 2012-2019 77 Table 29: Gastrointestinal Therapeutics Market, UK, Crohn's Disease, Market Forecast, 2012-2019 77 Table 30: Gastrointestinal Therapeutics Market, France, Irritable Bowel Syndrome, Market Forecast, 2012-2019 77 Table 31: Gastrointestinal Therapeutics Market, France, Ulcerative Colitis, Market Forecast, 2012-2019 78 Table 32: Gastrointestinal Therapeutics Market, France, Crohn's Disease, Market Forecast, 2012-2019 78 Table 33: Gastrointestinal Therapeutics Market, Germany, Irritable Bowel Syndrome, Market Forecast, 2012-2019 78 Table 34: Gastrointestinal Therapeutics Market, Germany, Ulcerative Colitis, Market Forecast, 20122019 79 Table 35: Gastrointestinal Therapeutics Market, Germany, Crohn's Disease, Market Forecast, 2012-2019 79 Table 36: Gastrointestinal Therapeutics Market, Italy, Irritable Bowel Syndrome, Market Forecast, 20122019 79 Table 37: Gastrointestinal Therapeutics Market, Italy, Ulcerative Colitis, Market Forecast, 2012-2019 80 Table 38: Gastrointestinal Therapeutics Market, Italy, Crohn's Disease, Market Forecast, 2012-2019 80

Table 39: Gastrointestinal Therapeutics Market, Spain, Irritable Bowel Syndrome, Market Forecast, 20122019 80 Table 40: Gastrointestinal Therapeutics Market, Spain, Ulcerative Colitis, Market Forecast, 2012-2019 81 Table 41: Gastrointestinal Therapeutics Market, Spain, Crohn's Disease, Market Forecast, 2012-2019 81 Table 42: Gastrointestinal Therapeutics Market, Japan, Irritable Bowel Syndrome, Market Forecast, 20122019 81 Table 43: Gastrointestinal Therapeutics Market, Japan, Ulcerative Colitis, Market Forecast, 2012-2019 82 Table 44: Gastrointestinal Therapeutics Market, Japan, Crohn's Disease, Market Forecast, 2012-2019 View Full Report with TOC @ http://www.radiantinsights.com/research/gastrointestinaltherapeutics-in-major-developed-markets-to-2019-new-drug-approvals-and-promising-pipeline-tocounter-declines-from-patent-expiries List of Figures Figure 1: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Algorithm of Ulcerative Colitis, 2007 19 Figure 2: Gastrointestinal Therapeutics Market, Global, Sales of Amitiza ($m), 2006-2012 26 Figure 3: Gastrointestinal Therapeutics Market, Global, Sales of Humira ($bn), 2006-2012 27 Figure 4: Gastrointestinal Therapeutics Market, Global, Sales of Remicade ($bn), 2006-2012 28 Figure 5: Gastrointestinal Therapeutics Market, Global, Sales of Simponi ($m), 2009-2012 29 Figure 6: Gastrointestinal Therapeutics Market, Global, Sales of Cimzia ($m), 2008-2012 30 Figure 7: Gastrointestinal Therapeutics Market, Global, Sales of Tysabri ($m), 2006-2012 31 Figure 8: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline, 2013 34 Figure 9: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline by Molecule Type, 2013 35 Figure 10: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline by Mechanism of Action, 2012 37 Figure 11: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline, 2013 39 Figure 12: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline by Molecule Type, 2013 40

Figure 13: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline by Mechanism of Action, 2013 42 Figure 14: Gastrointestinal Therapeutics Market, Global, Crohn's Disease, Pipeline, 2013 44 Figure 15: Gastrointestinal Therapeutics Market, Global, Crohn's Disease, Pipeline by Molecule Type, 2013 45 Figure 16: Gastrointestinal Therapeutics Market, Global, Crohn's Disease, Pipeline by Mechanism of Action, 2013 47 Figure 17: Gastrointestinal Therapeutics Market, Major Developed Markets, Market Size ($bn), 20122019 50 Figure 18: Gastrointestinal Therapeutics Market, US, Market Size ($bn), 2012-2019 52 View Full Report with TOC @ http://www.radiantinsights.com/research/gastrointestinaltherapeutics-in-major-developed-markets-to-2019-new-drug-approvals-and-promising-pipeline-tocounter-declines-from-patent-expiries Figure 19: Gastrointestinal Therapeutics Market, Top Five European Countries, Market Size ($bn), 20122019 54 Figure 20: Gastrointestinal Therapeutics Market, Canada, Market Size ($m), 2012-2019 56 Figure 21: Gastrointestinal Therapeutics Market, Japan, Market Size ($m), 2012-2019 58 Figure 22: Gastrointestinal Therapeutics Market, Global, Deals, 2006-2013 62 Figure 23: Gastrointestinal Therapeutics Market, Global, Co-Development Deals, 2006-2013 63 Figure 24: Gastrointestinal Therapeutics Market, Global, Licensing Deals, 2006-2013 65 Figure 25: GBI Research Market Forecasting Model 89 About Radiant Insights Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Information, Visit Radiant Insights Contact: Michelle Thoras

Corporate Sales Specialist, USA Radiant Insights, Inc Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com Blog URL: http://radiantinsights.weebly.com/